Obesity changes the human gut mycobiome
Rodríguez, M. Mar
Chaves, Felipe Javier
Chacón, Matilde R.
Fernández Real, José Manuel
MetadataShow full item record
The human intestine is home to a diverse range of bacterial and fungal species, forming an ecological community that contributes to normal physiology and disease susceptibility. Here, the fungal microbiota (mycobiome) in obese and non-obese subjects was characterized using Internal Transcribed Spacer
(ITS)-based sequencing. The results demonstrate that obese patients could be discriminated by their specific fungal composition, which also distinguished metabolically “healthy” from “unhealthy” obesity. Clusters according to genus abundance co-segregated with body fatness, fasting triglycerides and HDL-cholesterol. A preliminary link to metabolites such as hexadecanedioic acid, caproic acid and N-acetyl-L-glutamic acid was also found. Mucor racemosus and M. fuscus were the species more represented in non-obese subjects compared to obese counterparts. Interestingly, the decreased relative abundance of the Mucor genus in obese subjects was reversible upon weight loss. Collectively, these findings suggest that manipulation of gut mycobiome communities might be a novel target in the treatment of obesity.
Is part ofScientific Reports, 2015, vol. 5, núm. 14600
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Rodríguez, M. Mar et al., 2015
Showing items related by title, author, creator and subject.
Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness Ruiz‑Plazas, Xavier; Rodríguez‑Gallego, Esther; Alves, Marta; Altuna Coy, Antonio; Lozano‑Bartolomé, Javier; Portero Otín, Manuel; García‑Fontgivell, Joan Francesc; Martínez‑González, Salomé; Segarra, José; Chacón, Matilde R. (BMC (part of Springer Nature), 2019)Background: Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment ...
Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain Cullell, Natalia; Carrera, Caty; Muiño, Elena; Torres-Aguila, Nuria-Paz; Cárcel-Márquez, Jara; González-Sánchez, Jonathan; Gallego Fabrega, Cristina; Molina, Jessica; Besora, Sarah; Sotoca, Javier; Buongiorno, Maria-Teresa; Jiménez-Conde, Jordi; Giralt-Steinhauer, Eva; de Torres-Chacón, Reyes; Montaner, Joan; Mancha, Fernando; Cabezas, Juan A.; Martí Fàbregas, Joan; Prats Sánchez, Luis; Camps Renom, Pol; Purroy Garcia, Francisco; Cambray Carner, Serafí; Freijo, María del Mar; Vives-Bauzá, Cristòfol; Tur, Silvia; Font, Maria-Àngels; López-Cancio, Elena; Hernandez-Perez, Maria; Obach, Victor; Calleja, Ana; Arenillas, Juan; Rodríguez-Yáñez, Manuel; Castillo, José; Sobrino, Tomas; Fernández-Cádenas, Israel; Krupinski, Jerzy (Nature Publishing Group, 2020)Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms ...
Carmona, Andrés; Agüera, Maria L.; Luna-Ruiz, Carlos; Buendía, Paula; Calleros-Basilio, Laura; García-Jerez, Andrea; Rodríguez-Puyol, Manuel; Arias, Manuel; Arias-Guillen, Marta; Arriba, Gabriel de; Ballarin, José; Bernis, Carmen; Fernández i Giráldez, Elvira; García-Rebollo, Sagrario; Mancha, Javier; Peso, Gloria del; Pérez, Estefanía; Poch, Esteban; Portolés, José M.; Rodríguez-Puyol, Diego; Sánchez-Villanueva, Rafael; Sarró, Felipe; Torres, Armando; Martín-Malo, Alejandro; Aljama, Pedro; Ramírez, Rafael; Carracedo, Júlia (American Physiological Society, 2017-04-01)Patients with Stage 5 chronic kidney disease who are on hemodialysis (HD) remain in a chronic inflammatory state, characterized by the accumulation of uremic toxins that induce endothelial damage and cardiovascular disease ...